Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc (NQ: BEAM )

30.16 -0.38 (-1.24%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 739,070
Open 30.26
Bid (Size) 30.00 (1)
Ask (Size) 30.72 (3)
Prev. Close 30.54
Today's Range 29.95 - 30.91
52wk Range 27.77 - 73.27
Shares Outstanding 72,397,631
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Beam Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
From Beam Therapeutics
Via Globe NewsWire
Where Beam Therapeutics Stands With Analysts
 
Via Benzinga

Performance

YTD
-19.19%
-19.19%
1 Month
-22.65%
-22.65%
3 Month
-20.80%
-20.80%
6 Month
-35.22%
-35.22%
1 Year
-48.93%
-48.93%

More News

Read More
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
Via Benzinga
Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer
From Beam Therapeutics
Via Globe NewsWire
Where Beam Therapeutics Stands With Analysts
Via Benzinga
Beam Therapeutics to Participate in the Barclays 2023 Global Healthcare Conference
From Beam Therapeutics
Via Globe NewsWire
3 CRISPR Gene Editing Stocks to Consider for Ground-Floor Investing
Via InvestorPlace
3 Game-Changing Stocks to Buy in March
Via The Motley Fool
The Top 7 Growth Stocks in Biotech
Via InvestorPlace
Beam Therapeutics to Participate in the 43rd Annual Cowen Healthcare Conference
From Beam Therapeutics
Via Globe NewsWire
Analyst Ratings for Beam Therapeutics
Via Benzinga
Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
From Beam Therapeutics
Via Globe NewsWire
Better Buy: Beam Therapeutics or Intellia Therapeutics?
Via The Motley Fool
Beam Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
From Beam Therapeutics
Via Globe NewsWire
3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129%
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023
Via Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
Via InvestorPlace
5 Top Stocks for February
Via The Motley Fool
3 Great Growth Stocks Down 20% or More to Buy Now
Via The Motley Fool
A New Bull Market Is Coming: 3 Stocks That Could Skyrocket
Via The Motley Fool
3 Stocks That Could Create Lasting Generational Wealth
Via The Motley Fool
Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones
From Beam Therapeutics
Via Globe NewsWire
Cathie Wood Gets Elon Musk's Attention Over Gene-Editing Therapy Potential: 'Investors Chased The Dream Then. Now, They're Running Away'
Via Benzinga
Beam Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Beam Therapeutics
Via Globe NewsWire
3 Under-the-Radar Biotech Stocks to Buy in 2022
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.